Prostate Cancer
Research

Volume 7 Supplement 1
January 2019

Home > Disciplines > Publications > Prostate Cancer Research > Volume 7, Year 2019 > Supplement 1, January

CONTENTS

▼

DIAGNOSIS
OVERALL MANAGEMENT
PROGNOSIS
TREATMENT

DIAGNOSIS

▲

.

Bashir U, Tree A, Mayer E, Levine D, Parker C, Dearnaley D, Oyen WJG.
Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy.
Eur J Nucl Med Mol Imaging. 2019 Jan 8. doi: 10.1007/s00259-018-4249-z. [Epub ahead of print]
Source . Similar articles

.

Giesel FL, Will L, Paddubny K, Kremer C, Rathke H, Radtke JP, Kopka K, Haufe S, Haberkorn U, Kratochwil C.
[18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty.
Clin Genitourin Cancer. 2018 Apr;16(2):111-113. doi: 10.1016/j.clgc.2017.11.008. Epub 2017 Dec 6.
Source . Similar articles

.

Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S, Schäfer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C.
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688. doi: 10.1007/s00259-016-3573-4. Epub 2016 Nov 26.
Source . Similar articles

.

Hupe MC, Philippi C, Roth D, Kümpers C, Ribbat-Idel J, Becker F, Joerg V, Duensing S, Lubczyk VH, Kirfel J, Sailer V, Kuefer R, Merseburger AS, Perner S, Offermann A.
Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis.
Front Oncol. 2018 Dec 20;8:623. doi: 10.3389/fonc.2018.00623. eCollection 2018.
Source . Similar articles

.

Regis L, Celma A, Planas J, Lopez R, Roche S, Lorente D, Placer J, Trilla E, Morote J.
The role of negative magnetic resonance imaging: can we safely avoid biopsy in P.I.-R.A.D.S. 2 as in P.I.-R.A.D.S. 1?
Scand J Urol. 2019 Jan 10:1-5. doi: 10.1080/21681805.2018.1551243. [Epub ahead of print]
Source . Similar articles

OVERALL MANAGEMENT

▲

.

[No authors listed]
Abstracts of the 19th Asia-Pacific Prostate Cancer Conference 2018, 22 - 25 August 2018, Brisbane, Australia. - 1. Issue Information.
BJU Int. 2018 Aug;122 Suppl 2:1-3. doi: https://doi.org/10.1111/bju.14471. First published: 18 August 2018
Source . Similar articles

.

[No authors listed]
Abstracts of the 19th Asia-Pacific Prostate Cancer Conference 2018, 22 - 25 August 2018, Brisbane, Australia. - 2. Clinical Urology.
BJU Int. 2018 Aug;122 Suppl 2:4-15. doi: https://doi.org/10.1111/bju.14472. First published: 18 August 2018
Source . Similar articles

.

[No authors listed]
Abstracts of the 19th Asia-Pacific Prostate Cancer Conference 2018, 22 - 25 August 2018, Brisbane, Australia. - 3. Nursing and Allied Health.
BJU Int. 2018 Aug;122 Suppl 2:16-22. doi: https://doi.org/10.1111/bju.14473. First published: 18 August 2018
Source . Similar articles

.

[No authors listed]
Abstracts of the 19th Asia-Pacific Prostate Cancer Conference 2018, 22 - 25 August 2018, Brisbane, Australia. - 4. Translational Science.
BJU Int. 2018 Aug;122 Suppl 2:23-38. doi: 10.1111/bju.14474. First published: 18 August 2018. Erratum in: BJU Int. 2018 Dec;122(6):E4. .
Source . Similar articles

.

[No authors listed]
Abstracts of the 19th Asia-Pacific Prostate Cancer Conference 2018, 22 - 25 August 2018, Brisbane, Australia. - 5. Author Index.
BJU Int. 2018 Aug;122 Suppl 2:39-41. doi: 10.1111/bju.14475. First published: 18 August 2018.
Source . Similar articles

PROGNOSIS

▲

.

Fossati N, Buffi NM, Haese A, Stephan C, Larcher A, McNicholas T, de la Taille A, Freschi M, Lughezzani G, Abrate A, Bini V, Palou Redorta J, Graefen M, Guazzoni G, Lazzeri M.
Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study.
Eur Urol. 2015 Jul;68(1):132-8. doi: 10.1016/j.eururo.2014.07.034. Epub 2014 Aug 16.
Source . Similar articles

.

Guazzoni G, Lazzeri M, Nava L, Lughezzani G, Larcher A, Scattoni V, Gadda GM, Bini V, Cestari A, Buffi NM, Freschi M, Rigatti P, Montorsi F.
Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
Eur Urol. 2012 Mar;61(3):455-66. doi: 10.1016/j.eururo.2011.10.038. Epub 2011 Nov 4.
Source . Similar articles

.

Iwamoto H, Izumi K, Kadono Y, Mizokami A.
Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20 - 100 ng / mL.
Int Braz J Urol. 2019 Jan-Feb;45(1):61-67. doi: 10.1590/S1677-5538.IBJU.2018.0143. Epub 2918 Oct 30.
Source . Similar articles

.

Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, Scattoni V, Bini V, Freschi M, Sussman A, Ghaleh B, Le Corvoisier P, Alberola Bou J, Esquena Fernández S, Graefen M, Guazzoni G.
Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.
Eur Urol. 2013 Jun;63(6):986-94. doi: 10.1016/j.eururo.2013.01.011. Epub 2013 Jan 24.
Source . Similar articles

.

Lazzeri, M., Lughezzani, G., Larcher, A., Lista, G., Gadda, G. M., Scattoni, V., … Guazzoni, G.
Reply to Sergey Tadtayev, Thomas A. McNicholas, and Gregory B. Boustead’s Letter to the Editor re: Giorgio Guazzoni, Massimo Lazzeri, Luciano Nava, et al. Preoperative Prostate-Specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer. Eur Urol 2012;61:455–66. European Urology, 62(1), e16–e17.
Eur Urol. 2012 Jul;62(1):author reply e16-7. doi: 10.1016/j.eururo.2012.04.029. Epub 2012 Apr 17.
Source . Similar articles
Referring to: Tadtayev S et al, Re: Giorgio Guazzoni, Massimo Lazzeri, Luciano Nava, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012;61:455-66. Eur Urol. 2012 Jul;62(1):e14-5; doi: 10.1016/j.eururo.2012.04.030. Epub 2012 Apr 17. Source .
In turn referring to: Guazzoni G et al., Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol. 2012 Mar;61(3):455-66. doi: 10.1016/j.eururo.2011.10.038. Epub 2011 Nov 4. Source .

.

Tadtayev S, McNicholas TA, Boustead GB.
Re: Giorgio Guazzoni, Massimo Lazzeri, Luciano Nava, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012;61:455-66.
Eur Urol. 2012 Jul;62(1):e14-5; doi: 10.1016/j.eururo.2012.04.030. Epub 2012 Apr 17.
Source . Similar articles
Referring to: Guazzoni G et al., Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol. 2012 Mar;61(3):455-66. doi: 10.1016/j.eururo.2011.10.038. Epub 2011 Nov 4. Source .

TREATMENT

▲

.

Bravo I.
Comment on 'Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study'.
Br J Cancer. 2018 Feb 6;118(3):e1. doi: 10.1038/bjc.2017.342. Epub 2017 Nov 16.
Source . Similar articles
Letter to the Editor referring to: Triggiani L et al., Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer. 2017 Jun 6;116(12):1520-1525. doi: 10.1038/bjc.2017.103. Epub 2017 Apr 27. Source .

.

Triggiani L, Mazzola R, Magrini SM, Alongi F, Buglione M.
Reply to 'Comment on 'Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study''.
Br J Cancer. 2018 Feb 6;118(3):e2. doi: 10.1038/bjc.2017.406. Epub 2017 Nov 16.
Source . Similar articles
Letter to the Editor referring to: Bravo I, Comment on 'Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study'. Br J Cancer. 2018 Feb 6;118(3):e1. doi: 10.1038/bjc.2017.342. Epub 2017 Nov 16. Source .

.

Triggiani L, Alongi F, Buglione M, Detti B, Santoni R, Bruni A, Maranzano E, Lohr F, D'Angelillo R, Magli A, Bonetta A, Mazzola R, Pasinetti N, Francolini G, Ingrosso G, Trippa F, Fersino S, Borghetti P, Ghirardelli P, Magrini SM.
Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study.
Br J Cancer. 2017 Jun 6;116(12):1520-1525. doi: 10.1038/bjc.2017.103. Epub 2017 Apr 27.
Source . Similar articles

bottom

▲